Meeting
2024 ASCO Annual Meeting
Use of cell-free DNA from ascites to identify variants and tumour evolution in a cohort of patients with advanced ovarian cancer.
Authors
Bonnita Werner
UNSW, Sydney, Australia
Bonnita Werner , Elyse Powell , Jennifer Duggan , Marilisa Cortesi , Yeh Chen Lee , Vivek Arora , Ramanand Athavale , Michael Dean , Kristina Warton , Caroline Ford
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 5547)
DOI
10.1200/JCO.2024.42.16_suppl.5547
Abstract #
5547
Poster Bd #
418
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Olaparib (O) in advanced triple negative breast cancer (aTNBC) patients (pts) with BRCA1/2 promoter methylation: GEICAM/2015-06 study (COMETA-Breast).
First Author: Juan De La Haba
Poster
2022 ASCO Annual Meeting
Novel use of ctDNA to identify muscle-invasive and non-organ-confined upper tract urothelial carcinoma.
First Author: Heather L Huelster
Poster
2021 ASCO Annual Meeting
Genetic assessment of hereditary breast and ovarian cancer in the Harris Health System: A five-year, single-center experience.
First Author: Nicole Higashiyama
Poster
2021 ASCO Annual Meeting
Neoadjuvant talazoparib (TALA) in patients (pts) with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Exploration of tumor BRCA mutational status and zygosity and overall mutational landscape in a phase 2 study.
First Author: Melinda L. Telli